ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease

M. F. Weiner; F. J. Bonte; R. Tintner; N. Ford; D. Svetlik; T. Riall

doi:10.1002/ddr.430260410

ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease

M. F. Weiner, F. J. Bonte, R. Tintner, N. Ford, D. Svetlik, T. Riall

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

The effects of the acute administration of the ACE inhibitor ceronapril were studied in 12 Alzheimer's disease (AD) patients and 2 age‐matched controls. A 4‐week open trial was performed with daily doses of 40–80 mg/day. Testing was performed at baseline and at 4 weeks using the Mini‐mental State Exam and the cognitive portion of the Alzheimer's Disease Assessment Scale as cognitive measures, and regional cerebral blood flow (rCBF) as determined by Xe 133 single‐photon emission computerized tomography as an indirect measure of brain metabolism. There was no effect on cognition and blood flow increased significantly only in the left temporal region. It was concluded that the acute administration of the ACE inhibitor ceronapril had no significant acute effect on cognitive function of rCBF in AD. © 1992 Wiley‐Liss, Inc.

Original language	English (US)
Pages (from-to)	467-471
Number of pages	5
Journal	Drug Development Research
Volume	26
Issue number	4
DOIs	https://doi.org/10.1002/ddr.430260410
State	Published - 1992

Keywords

ceronapril
dementia
rCBF

ASJC Scopus subject areas

Drug Discovery

Access to Document

10.1002/ddr.430260410

Cite this

@article{c38201096adb4038a4b6a782117f9046,

title = "ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease",

abstract = "The effects of the acute administration of the ACE inhibitor ceronapril were studied in 12 Alzheimer's disease (AD) patients and 2 age‐matched controls. A 4‐week open trial was performed with daily doses of 40–80 mg/day. Testing was performed at baseline and at 4 weeks using the Mini‐mental State Exam and the cognitive portion of the Alzheimer's Disease Assessment Scale as cognitive measures, and regional cerebral blood flow (rCBF) as determined by Xe 133 single‐photon emission computerized tomography as an indirect measure of brain metabolism. There was no effect on cognition and blood flow increased significantly only in the left temporal region. It was concluded that the acute administration of the ACE inhibitor ceronapril had no significant acute effect on cognitive function of rCBF in AD. {\textcopyright} 1992 Wiley‐Liss, Inc.",

keywords = "ceronapril, dementia, rCBF",

author = "Weiner, {M. F.} and Bonte, {F. J.} and R. Tintner and N. Ford and D. Svetlik and T. Riall",

year = "1992",

doi = "10.1002/ddr.430260410",

language = "English (US)",

volume = "26",

pages = "467--471",

journal = "Drug Development Research",

issn = "0272-4391",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease

AU - Weiner, M. F.

AU - Bonte, F. J.

AU - Tintner, R.

AU - Ford, N.

AU - Svetlik, D.

AU - Riall, T.

PY - 1992

Y1 - 1992

N2 - The effects of the acute administration of the ACE inhibitor ceronapril were studied in 12 Alzheimer's disease (AD) patients and 2 age‐matched controls. A 4‐week open trial was performed with daily doses of 40–80 mg/day. Testing was performed at baseline and at 4 weeks using the Mini‐mental State Exam and the cognitive portion of the Alzheimer's Disease Assessment Scale as cognitive measures, and regional cerebral blood flow (rCBF) as determined by Xe 133 single‐photon emission computerized tomography as an indirect measure of brain metabolism. There was no effect on cognition and blood flow increased significantly only in the left temporal region. It was concluded that the acute administration of the ACE inhibitor ceronapril had no significant acute effect on cognitive function of rCBF in AD. © 1992 Wiley‐Liss, Inc.

AB - The effects of the acute administration of the ACE inhibitor ceronapril were studied in 12 Alzheimer's disease (AD) patients and 2 age‐matched controls. A 4‐week open trial was performed with daily doses of 40–80 mg/day. Testing was performed at baseline and at 4 weeks using the Mini‐mental State Exam and the cognitive portion of the Alzheimer's Disease Assessment Scale as cognitive measures, and regional cerebral blood flow (rCBF) as determined by Xe 133 single‐photon emission computerized tomography as an indirect measure of brain metabolism. There was no effect on cognition and blood flow increased significantly only in the left temporal region. It was concluded that the acute administration of the ACE inhibitor ceronapril had no significant acute effect on cognitive function of rCBF in AD. © 1992 Wiley‐Liss, Inc.

KW - ceronapril

KW - dementia

KW - rCBF

UR - http://www.scopus.com/inward/record.url?scp=0026707201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026707201&partnerID=8YFLogxK

U2 - 10.1002/ddr.430260410

DO - 10.1002/ddr.430260410

M3 - Article

AN - SCOPUS:0026707201

SN - 0272-4391

VL - 26

SP - 467

EP - 471

JO - Drug Development Research

JF - Drug Development Research

IS - 4

ER -

ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this